leisure time -WSS

leisure time

author：comprehensive 2025-09-07 11:15:27 - browse：742

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Gene therapy has helped boys walk. Can scientists keep it that way?

WSS

New guidelines on severe brain injury complicate already difficult decisions

Novavax promises a turnaround & Lilly roils the obesity market

State Dept. review finds Biden bears some blame for Afghanistan failures

Ask STAT: What do you want to know about ChatGPT in medicine?

3 hurdles to bringing medical devices to the U.S. market

Tori Bowie and the unacceptable rates of Black maternal death

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

What does generative AI mean for health care? We asked experts

Moonlake's readout produced a cash windfall. Risks remain

DIEP, the 'gold standard' of breast reconstruction, is under threat

The science behind Janet Jackson's pregnancy at 49

Alkermes shareholders re

State Dept. review finds Biden bears some blame for Afghanistan failures

Supreme Court strikes down use of affirmative action

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The high cost of giving birth even with insurance

With FDA staff opposed to Sarepta therapy, top official intervened

hotspot

Activists slam private health insurers over coverage restrictions

As demand for Covid shots wanes, Moderna seeks its next success

With FDA staff opposed to Sarepta therapy, top official intervened

Death of patient in Alzheimer’s trial raises question of possible risks

New air purifier tech could be key to improving indoor air quality

New air purifier tech could be key to improving indoor air quality

knowledge

focus

focus

focus